Acute Myeloid Leukemia — Many Diseases, Many Treatments — NEJM
Acute Myeloid Leukemia — Many Diseases, Many Treatments
Elihu Estey, M.D.
N Engl J Med 2016; 375:2094-2095November 24, 2016DOI: 10.1056/NEJMe1611424
This article has no abstract; the first 100 words appear below.
Patients with acute myeloid leukemia (AML) generally receive stereotypical treatment.1 For example, young patients receive cytarabine for 7 days and an anthracycline for 3 days (known as “7+3 induction”). Thus treated, some groups, predictably, have an approximately 50% chance of “cure” (“favorable risk”) whereas others, also predictably, have a survival of 6 to 18 months (“unfavorable risk”). This nonrandom heterogeneity after homogeneous treatment suggests that, like pneumonia, AML is several diseases. Today, AML is primarily defined according to leukemia-cell karyotype and an increasing number of molecular aberrations.2 It follows that different types of AML should ideally be treated differently. This . . .
Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.
From the Division of Hematology, University of Washington Medical Center, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle.